{"url":"https://lda.senate.gov/api/v1/filings/f8d334e5-a6d9-4d0d-a948-7cd4e81ea2aa/","filing_uuid":"f8d334e5-a6d9-4d0d-a948-7cd4e81ea2aa","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2022,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/f8d334e5-a6d9-4d0d-a948-7cd4e81ea2aa/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Darren Willcox","dt_posted":"2023-01-19T20:34:02-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1455 Pennsylvania Avenue, NW","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":400605842,"url":"https://lda.senate.gov/api/v1/registrants/400605842/","house_registrant_id":null,"name":"W STRATEGIES, LLC","description":"Government Affairs Consulting Firm.","address_1":"1455 Pennsylvania Avenue, NW","address_2":"Suite 400","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DARREN WILLCOX","contact_telephone":"+1 202-494-6268","dt_updated":"2026-01-30T17:48:20.361860-05:00"},"client":{"id":207510,"url":"https://lda.senate.gov/api/v1/clients/207510/","client_id":366,"name":"IOVANCE BIOTHERAPEUTICS, INC.","general_description":"Biopharmaceutical company.","client_government_entity":false,"client_self_select":null,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Education around TIL cancer therapies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":51473,"prefix":null,"prefix_display":null,"first_name":"DARREN","nickname":null,"middle_name":null,"last_name":"WILLCOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"FY 2022 IPPS Rule as it relates to cell therapies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":51473,"prefix":null,"prefix_display":null,"first_name":"DARREN","nickname":null,"middle_name":null,"last_name":"WILLCOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}